A group of vaccine developers, biotech firms and public health institutes, including Bavarian Nordic and Sanofi, has secured framework contracts under a €225 million EU initiative to accelerate the development of next-generation influenza vaccines.
ADVERTISEMENT
Log in here to read the desired article.
A group of vaccine developers, biotech firms and public health institutes, including Bavarian Nordic and Sanofi, has secured framework contracts under a €225 million EU initiative to accelerate the development of next-generation influenza vaccines.

